Skip to main content

Advertisement

Log in

Very early infective endocarditis after transcatheter aortic valve replacement

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Scarce data exist about early infective endocarditis (IE) after trans-catheter aortic valve replacement (TAVR).

Objective

The objective was to evaluate the characteristics, management, and outcomes of very early (VE) IE (≤ 30 days) after TAVR.

Methods

This multicenter study included a total of 579 patients from the Infectious Endocarditis after TAVR International Registry who had the diagnosis of definite IE following TAVR.

Results

Ninety-one patients (15.7%) had VE-IE. Factors associated with VE-IE (vs. delayed IE (D-IE)) were female gender (p = 0.047), the use of self-expanding valves (p < 0.001), stroke (p = 0.019), and sepsis (p < 0.001) after TAVR. Staphylococcus aureus was the main pathogen among VE-IE patients (35.2% vs. 22.7% in the D-IE group, p = 0.012), and 31.2% of Staphylococcus aureus infections in the VE-IE group were methicillin-resistant (vs. 14.3% in the D-IE group, p = 0.001). The second-most common germ was enterococci (34.1% vs. 24.4% in D-IE cases, p = 0.05). VE-IE was associated with very high in-hospital (44%) and 1-year (54%) mortality rates. Acute renal failure following TAVR (p = 0.001) and the presence of a non-enterococci pathogen (p < 0.001) were associated with an increased risk of death.

Conclusion

A significant proportion of IE episodes following TAVR occurs within a few weeks following the procedure and are associated with dismal outcomes. Some baseline and TAVR procedural factors were associated with VE-IE, and Staphylococcus aureus and enterococci were the main causative pathogens. These results may help to select the more appropriate antibiotic prophylaxis in TAVR procedures and guide the initial antibiotic therapy in those cases with a clinical suspicion of IE.

Graphical abstract

Very early infective endocarditis after trans-catheter aortic valve replacement. VE-IE indicates very early infective endocarditis (≤30 days post TAVR). D-IE indicates delayed infective endocarditis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

D-IE:

Delayed infective endocarditis

IE:

Infective endocarditis

IQR:

Interquartile range

PVE:

Prosthetic valve endocarditis

TAVR:

Trans-catheter aortic valve replacement

THV:

Trans-catheter heart valve

VE-IE:

Very early infective endocarditis

References

  1. Regueiro A, Linke A, Latib A et al (2016) Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA 316:1083–1092. https://doi.org/10.1001/jama.2016.12347

    Article  PubMed  Google Scholar 

  2. Ando T, Ashraf S, Villablanca PA et al (2019) Meta-analysis comparing the incidence of infective endocarditis following transcatheter aortic valve implantation versus surgical aortic valve replacement. Am J Cardiol 123:827–832. https://doi.org/10.1016/j.amjcard.2018.11.031

    Article  PubMed  Google Scholar 

  3. Fauchier L, Bisson A, Herbert J et al (2020) Incidence and outcomes of infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement. Clin Microbiol Infect 26:1368–1374. https://doi.org/10.1016/j.cmi.2020.01.036

    Article  CAS  PubMed  Google Scholar 

  4. Summers MR, Leon MB, Smith CR et al (2019) Prosthetic valve endocarditis after TAVR and SAVR: insights from the PARTNER trials. Circulation 140:1984–1994. https://doi.org/10.1161/CIRCULATIONAHA.119.041399

    Article  PubMed  Google Scholar 

  5. Butt JH, Ihlemann N, De Backer O et al (2019) Long-term risk of infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 73:1646–1655. https://doi.org/10.1016/j.jacc.2018.12.078

    Article  PubMed  Google Scholar 

  6. Stortecky S, Heg D, Tueller D et al (2020) Infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 75:3020–3030. https://doi.org/10.1016/j.jacc.2020.04.044

    Article  PubMed  Google Scholar 

  7. Habib G, Lancellotti P, Antunes MJ et al (2015) 2015 ESC Guidelines for the management of infective endocarditis. the task force for the management of infective endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36:3075–3128. https://doi.org/10.1093/eurheartj/ehv319

    Article  PubMed  Google Scholar 

  8. Kappetein AP, Head SJ, Généreux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60:1438–1454. https://doi.org/10.1016/j.jacc.2012.09.001

    Article  PubMed  Google Scholar 

  9. Mehta RL, Kellum JA, Shah SV et al (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31. https://doi.org/10.1186/cc5713

    Article  PubMed  PubMed Central  Google Scholar 

  10. Siciliano RF, Randi BA, Gualandro DM et al (2018) Early-onset prosthetic valve endocarditis definition revisited: prospective study and literature review. Int J Infect Dis 67:3–6. https://doi.org/10.1016/j.ijid.2017.09.004

    Article  PubMed  Google Scholar 

  11. Benito N, Miró JM, de Lazzari E et al (2009) Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med 150:586–594. https://doi.org/10.7326/0003-4819-150-9-200905050-00004

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fernández-Hidalgo N, Almirante B, Tornos P et al (2008) Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis 47:1287–1297. https://doi.org/10.1086/592576

    Article  PubMed  Google Scholar 

  13. Graffunder EM, Venezia RA (2002) Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 49:999–1005. https://doi.org/10.1093/jac/dkf009

    Article  CAS  PubMed  Google Scholar 

  14. Roghmann M-C, Lydecker AD, Hittle L et al (2017) Comparison of the microbiota of older adults living in nursing homes and the community. mSphere 2:e00210-17. https://doi.org/10.1128/mSphere.00210-17

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bonten MJ, Hayden MK, Nathan C et al (1996) Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. The Lancet 348:1615–1619. https://doi.org/10.1016/S0140-6736(96)02331-8

    Article  CAS  Google Scholar 

  16. Miller WR, Munita JM, Arias CA (2014) Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther 12:1221–1236. https://doi.org/10.1586/14787210.2014.956092

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Chambers HF, DeLeo FR (2009) Waves of resistance: Staphylococcus aureus in the Antibiotic Era. Nat Rev Microbiol 7:629–641. https://doi.org/10.1038/nrmicro2200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Engelman R, Shahian D, Shemin R, et al (2007) The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: Antibiotic Choice. Ann Thorac Surg 83:1569–1576. https://doi.org/10.1016/j.athoracsur.2006.09.046

  19. Finkelstein R, Rabino G, Mashiah T et al (2002) Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 123:326–332. https://doi.org/10.1067/mtc.2002.119698

    Article  CAS  PubMed  Google Scholar 

  20. Chenoweth CE, DePestel DD, Prager RL (2005) Are cephalosporins adequate for antimicrobial prophylaxis for cardiac surgery involving implants? Clin Infect Dis 41:122–123. https://doi.org/10.1086/430831 (author reply 123-124)

    Article  PubMed  Google Scholar 

  21. Baddour LM, Epstein AE, Erickson CC et al (2010) Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 121:458–477. https://doi.org/10.1161/CIRCULATIONAHA.109.192665

    Article  PubMed  Google Scholar 

  22. Conen A, Stortecky S, Moreillon P et al (2021) A review of recommendations for infective endocarditis prevention in patients undergoing transcatheter aortic valve implantation. EuroIntervention 16:1135–1140. https://doi.org/10.4244/EIJ-D-19-00993

    Article  PubMed  Google Scholar 

  23. Kachroo S, Dao T, Zabaneh F et al (2006) Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother 40:381–385. https://doi.org/10.1345/aph.1G565

    Article  CAS  PubMed  Google Scholar 

  24. Sambola A, Fernández-Hidalgo N, Almirante B et al (2010) Sex differences in native-valve infective endocarditis in a single tertiary-care hospital. Am J Cardiol 106:92–98. https://doi.org/10.1016/j.amjcard.2010.02.019

    Article  PubMed  Google Scholar 

  25. Aksoy O, Meyer LT, Cabell CH et al (2007) Gender differences in infective endocarditis: pre- and co-morbid conditions lead to different management and outcomes in female patients. Scand J Infect Dis 39:101–107. https://doi.org/10.1080/00365540600993285

    Article  PubMed  Google Scholar 

  26. Chandrasekhar J, Dangas G, Yu J et al (2016) Sex-based differences in outcomes with transcatheter aortic valve therapy: TVT registry from 2011 to 2014. J Am Coll Cardiol 68:2733–2744. https://doi.org/10.1016/j.jacc.2016.10.041

    Article  PubMed  Google Scholar 

  27. Wang HE, Gamboa C, Warnock DG, Muntner P (2011) Chronic kidney disease and risk of death from infection. Am J Nephrol 34:330–336. https://doi.org/10.1159/000330673

    Article  PubMed  PubMed Central  Google Scholar 

  28. Murdoch DR, Corey GR, Hoen B et al (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169:463–473. https://doi.org/10.1001/archinternmed.2008.603

    Article  PubMed  PubMed Central  Google Scholar 

  29. Del Val D, Trottier M, Alperi A et al (2020) 18F-Fluorodeoxyglucose uptake pattern in noninfected transcatheter aortic valves. Circ Cardiovasc Imaging 13:e011749. https://doi.org/10.1161/CIRCIMAGING.120.011749

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the Infectious Endocarditis after TAVR International Registry Investigators for their substantial contribution to data collection and research (the list of investigators is available in the supplemental material). Dr Rodés-Cabau holds the Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions. Dr. Panagides has received a research grant from the “Mediterranean Academic Research and Studies in Cardiology” association (MARS Cardio).

Funding

There was no specific funding for this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Josep Rodés-Cabau.

Ethics declarations

Conflict of interest

Josep Rodés-Cabau has received institutional research grants from Edwards Lifesciences, Medtronic, and Boston Scientific. Vassili Panagides has received institutional research grants from Medtronic, Boston Scientific and Microport. C. Herrmann has received institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic and consulting fees from Edwards Lifesciences and Medtronic. Jan Malte Sinning reports speaker honoraria from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic and research grants from Boston Scientific, Edwards Lifesciences, and Medtronic, outside the submitted work. Kim Won-Keun reports personal fees from Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, and Meril, outside the submitted work. Oliver Husser reports personal fees from Boston Scientific and payments from Abbott. Norman Mangner reports personal fees from Edwards Lifesciences, Medtronic, Biotronik, Novartis, Sanofi Genzyme, AstraZeneca, Pfizer, and Bayer, outside the submitted work. All other authors report no potential conflicts.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panagides, V., Abdel-Wahab, M., Mangner, N. et al. Very early infective endocarditis after transcatheter aortic valve replacement. Clin Res Cardiol 111, 1087–1097 (2022). https://doi.org/10.1007/s00392-022-01998-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-022-01998-0

Keywords

Navigation